Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dolby Laboratories (DLB) EBITDA (2016 - 2025)

Historic EBITDA for Dolby Laboratories (DLB) over the last 17 years, with Q4 2025 value amounting to $62.2 million.

  • Dolby Laboratories' EBITDA fell 2218.33% to $62.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $247.2 million, marking a year-over-year decrease of 909.83%. This contributed to the annual value of $265.0 million for FY2025, which is 256.77% up from last year.
  • According to the latest figures from Q4 2025, Dolby Laboratories' EBITDA is $62.2 million, which was down 2218.33% from $29.7 million recorded in Q3 2025.
  • In the past 5 years, Dolby Laboratories' EBITDA ranged from a high of $109.2 million in Q1 2023 and a low of -$3.5 million during Q3 2023
  • Its 5-year average for EBITDA is $59.4 million, with a median of $51.9 million in 2021.
  • Per our database at Business Quant, Dolby Laboratories' EBITDA tumbled by 11288.92% in 2023 and then surged by 142667.43% in 2024.
  • Over the past 5 years, Dolby Laboratories' EBITDA (Quarter) stood at $90.6 million in 2021, then grew by 3.87% to $94.1 million in 2022, then dropped by 29.62% to $66.2 million in 2023, then rose by 20.63% to $79.9 million in 2024, then decreased by 22.18% to $62.2 million in 2025.
  • Its EBITDA was $62.2 million in Q4 2025, compared to $29.7 million in Q3 2025 and $47.6 million in Q2 2025.